PATHOLOGIC STAGE IIIA CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIA CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIA CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIA CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for transplant patients with advanced skin cancer: immune drugs may control tumors without losing the kidney
Disease control OngoingThis early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated ki…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Radiation boosts immunotherapy in rare skin cancer trial
Disease control OngoingThis study compares the drug pembrolizumab (an immunotherapy that helps the immune system fight cancer) alone versus pembrolizumab plus precise, high-dose radiation (SBRT) in people with advanced Merkel cell carcinoma that has spread. The goal is to see if adding radiation helps …
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:03 UTC